EGFR and non-small cell lung carcinoma: These analogues are significantly more effective towards EGFR-mutant NSCLC cells than Spautin-1 and act as potent never in mitosis A related kinase 4 (NEK4) inhibitors (IC50~1 μM) with moderate selectivity over other kinases.